Avacta strengthens CNS Dx know-how with Theragenetics buy
This article was originally published in Clinica
Executive Summary
Charging along the acquisition trail, AIM-listed firm Avacta has bagged its second purchase in as many weeks with a £2m ($3m) cash-and-stock deal for Theragenetics.